These findings collectively indicate that the selective antitumor activity of zardaverine is closely related to the regulation of cell cycle-associated proteins and that low expression of Rb is likely to be a biomarker for zardaverine-sensitive cancer cells. The gene discussed is PROS1; the disease is cancer.